5,438 Shares in Elevance Health, Inc. (NYSE:ELV) Bought by Virtu Financial LLC

Virtu Financial LLC bought a new stake in Elevance Health, Inc. (NYSE:ELV - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,438 shares of the company's stock, valued at approximately $2,828,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Raelipskie Partnership acquired a new position in shares of Elevance Health during the 3rd quarter worth about $26,000. PSI Advisors LLC acquired a new position in Elevance Health during the third quarter worth approximately $27,000. Strategic Financial Concepts LLC bought a new stake in Elevance Health in the second quarter valued at approximately $30,000. Eastern Bank bought a new position in shares of Elevance Health during the 3rd quarter worth approximately $31,000. Finally, Dunhill Financial LLC increased its holdings in shares of Elevance Health by 57.8% during the 3rd quarter. Dunhill Financial LLC now owns 71 shares of the company's stock worth $37,000 after acquiring an additional 26 shares during the last quarter. 89.24% of the stock is owned by institutional investors.

Elevance Health Price Performance

Shares of ELV stock traded down $6.76 on Thursday, reaching $378.80. The company had a trading volume of 943,007 shares, compared to its average volume of 1,214,947. The business's 50-day moving average is $426.92 and its 200 day moving average is $496.22. Elevance Health, Inc. has a one year low of $378.78 and a one year high of $567.26. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $87.85 billion, a PE ratio of 14.06, a price-to-earnings-growth ratio of 1.14 and a beta of 0.83.

Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings results on Thursday, October 17th. The company reported $8.37 EPS for the quarter, missing analysts' consensus estimates of $9.66 by ($1.29). The firm had revenue of $44.72 billion for the quarter, compared to analyst estimates of $43.47 billion. Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business posted $8.99 earnings per share. Equities research analysts forecast that Elevance Health, Inc. will post 32.96 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 20th. Stockholders of record on Thursday, December 5th will be given a dividend of $1.63 per share. The ex-dividend date of this dividend is Thursday, December 5th. This represents a $6.52 dividend on an annualized basis and a dividend yield of 1.72%. Elevance Health's dividend payout ratio (DPR) is presently 23.77%.

Analyst Ratings Changes

Several brokerages have issued reports on ELV. Mizuho cut their price target on Elevance Health from $585.00 to $505.00 and set an "outperform" rating for the company in a report on Tuesday, November 5th. TD Cowen cut their target price on shares of Elevance Health from $589.00 to $484.00 and set a "buy" rating for the company in a research note on Monday, October 21st. Cantor Fitzgerald decreased their price target on shares of Elevance Health from $600.00 to $485.00 and set an "overweight" rating on the stock in a research note on Friday, October 18th. Barclays cut their price objective on shares of Elevance Health from $622.00 to $501.00 and set an "overweight" rating for the company in a research report on Tuesday, October 22nd. Finally, Argus downgraded Elevance Health from a "buy" rating to a "hold" rating in a research report on Friday, October 18th. One analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $539.20.

Insider Activity

In related news, EVP Charles Morgan Kendrick, Jr. sold 7,417 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $432.14, for a total transaction of $3,205,182.38. Following the completion of the sale, the executive vice president now directly owns 8,423 shares of the company's stock, valued at approximately $3,639,915.22. This trade represents a 46.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.29% of the stock is currently owned by company insiders.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.